The Jordan Food and Drug Administration (JFDA) has approved registration of 90 medicines, aimed to achieve Jordan's drug security, in accordance with the 2024 Special Drug Registration Instructions.
In a statement Sunday, JFDA Director General, Dr. Nizar Mheidat, said the administration received 147 registration applications on the Drug Security List from relevant warehouses and local manufacturing companies.
Mheidat added that the drug items approved for registration are mainly life-saving medications for chronic diseases, heart illnesses and cancer, including medicines required for government tenders or the local market and are unavailable locally.
Mheidat noted the JFDA is 'continuously' working to update these items based on drug inventory indicators and spur local pharmaceutical companies to manufacture and register medicines that may see shortages in their supply to the local market.
Mheidat stated this process encourages companies to prioritize registration, inspection, and the necessary technical consultations when submitting their applications.
Meanwhile, he indicated that some applications are still pending to complete submission of the necessary documents. Petra
The Jordan Food and Drug Administration (JFDA) has approved registration of 90 medicines, aimed to achieve Jordan's drug security, in accordance with the 2024 Special Drug Registration Instructions.
In a statement Sunday, JFDA Director General, Dr. Nizar Mheidat, said the administration received 147 registration applications on the Drug Security List from relevant warehouses and local manufacturing companies.
Mheidat added that the drug items approved for registration are mainly life-saving medications for chronic diseases, heart illnesses and cancer, including medicines required for government tenders or the local market and are unavailable locally.
Mheidat noted the JFDA is 'continuously' working to update these items based on drug inventory indicators and spur local pharmaceutical companies to manufacture and register medicines that may see shortages in their supply to the local market.
Mheidat stated this process encourages companies to prioritize registration, inspection, and the necessary technical consultations when submitting their applications.
Meanwhile, he indicated that some applications are still pending to complete submission of the necessary documents. Petra
The Jordan Food and Drug Administration (JFDA) has approved registration of 90 medicines, aimed to achieve Jordan's drug security, in accordance with the 2024 Special Drug Registration Instructions.
In a statement Sunday, JFDA Director General, Dr. Nizar Mheidat, said the administration received 147 registration applications on the Drug Security List from relevant warehouses and local manufacturing companies.
Mheidat added that the drug items approved for registration are mainly life-saving medications for chronic diseases, heart illnesses and cancer, including medicines required for government tenders or the local market and are unavailable locally.
Mheidat noted the JFDA is 'continuously' working to update these items based on drug inventory indicators and spur local pharmaceutical companies to manufacture and register medicines that may see shortages in their supply to the local market.
Mheidat stated this process encourages companies to prioritize registration, inspection, and the necessary technical consultations when submitting their applications.
Meanwhile, he indicated that some applications are still pending to complete submission of the necessary documents. Petra
comments
JFDA approves registration of 90 medicines
view mode :
Full
Main image
without images
view comments
JFDA approves registration of 90 medicines
The Jordan Food and Drug Administration (JFDA) has approved registration of 90 medicines, aimed to achieve Jordan's drug security, in accordance with the 2024 Special Drug Registration Instructions.
In a statement Sunday, JFDA Director General, Dr. Nizar Mheidat, said the administration received 147 registration applications on the Drug Security List from relevant warehouses and local manufacturing companies.
Mheidat added that the drug items approved for registration are mainly life-saving medications for chronic diseases, heart illnesses and cancer, including medicines required for government tenders or the local market and are unavailable locally.
Mheidat noted the JFDA is 'continuously' working to update these items based on drug inventory indicators and spur local pharmaceutical companies to manufacture and register medicines that may see shortages in their supply to the local market.
Mheidat stated this process encourages companies to prioritize registration, inspection, and the necessary technical consultations when submitting their applications.
Meanwhile, he indicated that some applications are still pending to complete submission of the necessary documents. Petra
comments